Teva Pharmaceutical Industries Limited (TEVA) share price fell -4.96% to $15.7 in the last trading session. The Market Cap of the company is $15.67 Billion. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 9.21%, whereas SMA50 and SMA200 are 10.48% and -35.44% respectively. The Average Volume of the company is 24.04 Million, while the Volume of the company in the last trading session was 30.47 Billion.
The Piotroski score is a discrete score ranging from 0-9 that shows nine criteria used to find out the strength of a company’s financial position. It is used to find out the best value stocks, 9 being the best. The company is given one point for every criteria that is met and no points if not met. Subsequently, the points are added up to determine the best value stocks.
TEVA’s mean Piotroski F-Score: 4 in the past 7 years.
The Altman Z-score is a statistical tool used to calculate the likelihood of a company’s bankruptcy. It depends on 5 financial ratios, which can be calculated from data found on a firm’s annual 10K report. A score above three means the company is not likely to go bankrupt, while score less than 1.8 suggests the firm is probably headed for bankruptcy.
TEVAs average Altman Z-Score: 0.34 in the past 7 years.
Free Cash Flow Growth
FCF is an indicator of a firm’s financial performance, measured as operating cash flow minus capital expenditures. It shows the cash a company is able to generate after spending the money need to maintain or grow its asset base. FCF is an important factor as it enables a company to pursue opportunities that boost shareholder value.
Teva Pharmaceutical Industries Limited’s average Free Cash Flow per Share Growth Rate was -44.5 percent during the past 12 months.
Book Value Growth
It is the net asset value of a company, calculated as total assets minus intangible assets and liabilities. Book value refers to the total amount a firm would be worth if it liquidated its assets and paid back all its liabilities.
Teva Pharmaceutical Industries Limited’s average Book Value per Share Growth Rate was -20.6 percent during the past 12 months.
Profitability and Growth Analysis
Teva Pharmaceutical Industries Limited (TEVA) shows its Return on Assets (ROA) value of -6.7 percent, while the Return on Equity (ROE) value is -21.8 percent and Return on Investment (ROI) value stands at 1.1 percent. The company’s Relative strength index is 59.15.
Analyst Recommendations Analysis
Among analysts who offered their Analysis on Teva Pharmaceutical Industries Limited (TEVA)—1 analysts issued Buy for the stock, 3 analysts gave Outperform rating, 18 think it’s a Hold, 6 issued Underperform, while 0 analyst gave a Sell rating. (These Recommendations are reported by Reuters and are only for the Current Month)
Quarterly Profit Outlook Analysis
A number of analysts offered their Estimated Earnings analysis for Teva Pharmaceutical Industries Limited (TEVA) for the current quarter. 22 analysts on average projected earnings of $0.75 per share for the current quarter. The High end of the forecast is $0.85 per share, while the Low end is $0.67 per share.
Quarterly Revenue Outlook Analysis
Average Revenue Estimate for the current quarter is $5.32 Billion, according to consensus forecast of 20 analysts. The High end of the Estimate is $5.63 Billion, while the Low end of the Estimate is $5.22 Billion. The company had Year Ago Sales of $6.27 Billion.